Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation).
The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults.
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK533768/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
